Recursion Pharmaceuticals

RXRXNASDAQ

Machine-learning-guided phenomics and automated drug discovery platform

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-10-02. Published by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.

text updated 2026-10-02 · archived: kept for reference, not maintained · where each field comes from

AI-enabled drug discoveryrare diseaseoncology

Key figures from SEC filings

We have not parsed a 10-Q or 10-K for RXRX yet, so this page shows no cash, burn or runway figure rather than an estimate. Revenue stage: Pre-revenue.

Upcoming catalysts

ELUCIDATE: GTAEXS617 in Advanced solid tumours — primary completion

2028-01

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneModerate

EXS73565: EXS73565 in Relapsed/refractory B-cell malignancies — primary completion

2028-06

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneMinor

EXS74539: EXS74539 in Select solid tumours — primary completion

2029-03

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneMinor

Pipeline

DrugIndicationPhaseExpected data
REC-994cerebral cavernous malformationPhase 2Not disclosed▼
REC-2282neurofibromatosis type 2-associated meningiomasPhase 2Not disclosed▼
REC-617solid tumorsPhase 1Not disclosed▼

Analysis

We have not yet written an analysis of Recursion Pharmaceuticals that is specific and current enough to publish. Earlier text here was removed rather than left up: on most profiles it was a template shared with other companies, and where a correction is listed above, it was written before the facts changed. The filing figures, pipeline and sourced catalysts on this page are current; the written thesis will be added from them.
Trade RXRX commission-free on Webullvia Webull · Affiliate

Comparable companies

SchrodingerRelay TherapeuticsExscientia

Sponsored

Get premium RXRX analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Recursion Pharmaceuticals has 8 Phase 2 or 3 studies on ClinicalTrials.gov: 1 completed, 3 stopped early, 4 ongoing.

1

Completed

3

Stopped early

4

Ongoing

Stopped early

  • ALDERPhase 2 · started 2024 · terminated

    REC-3964 in recurrent clostridioides difficile infection · n=3

    Reason given: Study was terminated due to sponsor decision. This decision was not related to safety concerns.

  • NCT06005974Phase 2 · started 2024 · terminated

    REC-4881 in axin1 gene mutation · n=18

    Reason given: Study was terminated due to sponsor decision. This decision was not related to safety concerns.

  • POPLAR-NF2Phase 2/3 · started 2022 · terminated

    REC-2282 in neurofibromatosis type 2 · n=25

    Reason given: Study was terminated due to sponsor decision. This decision was not related to safety concerns with REC-2282.

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.